We are live on ! Find out more
OM

Opaleye Management Portfolio holdings

AUM $1.1B
1-Year Est. Return 197.64%
This Fund
S&P 500
This Quarter Est. Return
+60.43%
1 Year Est. Return
+197.64%
3 Year Est. Return
+748.31%
5 Year Est. Return
+1,163.14%
10 Year Est. Return
+87,953.74%
AUM
$242M
AUM Growth
+$20.3M
Cap. Flow
-$14.2M
Cap. Flow %
-5.88%
Top 10 Hldgs %
67.89%
Holding
53
New
6
Increased
20
Reduced
10
Closed
11

Top Buys

Rank Stock Value
1
RYTM icon
Rhythm Pharmaceuticals
RYTM
+$8.33M
2
TELA icon
TELA Bio
TELA
+$3.26M
3
OCUL icon
Ocular Therapeutix
OCUL
+$2.47M
4
EWTX icon
Edgewise Therapeutics
EWTX
+$1.86M
5
LRMR icon
Larimar Therapeutics
LRMR
+$1.83M

Top Sells

Rank Stock Value
1
KNSA icon
Kiniksa Pharmaceuticals
KNSA
+$7.89M
2
RETA
Reata Pharmaceuticals, Inc. Class A Common Stock
RETA
+$5.58M
3
INBX
Inhibrx, Inc. Common Stock
INBX
+$5.36M
4
MASS icon
908 Devices
MASS
+$3.43M
5
CLDX icon
Celldex Therapeutics
CLDX
+$2.43M

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
MRNS
51
DELISTED
Marinus Pharmaceuticals, Inc
MRNS
– –
-68,900
Closed -$333K
RETA
52
DELISTED
Reata Pharmaceuticals, Inc. Class A Common Stock
RETA
– –
-183,750
Closed -$5.58M
FMTX
53
DELISTED
Forma Therapeutics Holdings, Inc. Common Stock
FMTX
– –
-58,700
Closed -$404K
1 2
3

Similar funds

CFO
CVA Family Office Denver, Colorado $1.1B AUM 26.6% 1-Year Est. Return
PFM
Premier Fund Managers Guildford, United Kingdom $1.1B AUM 14.42% 1-Year Est. Return
HBCM
Heron Bay Capital Management Bloomfield Hills, Michigan $1.1B AUM 11.31% 1-Year Est. Return
HAS
HBW Advisory Services Simi Valley, California $1.11B AUM 25.66% 1-Year Est. Return
AI
Aperture Investors New York $1.11B AUM 81.44% 1-Year Est. Return
TPA
Trivium Point Advisory Westport, Connecticut $1.1B AUM 28.81% 1-Year Est. Return
ZDA
Zweig-DiMenna Associates New York $1.1B AUM 171.86% 1-Year Est. Return
NW
Naviter Wealth Little Rock, Arkansas $1.1B AUM 33.28% 1-Year Est. Return

Opaleye Management's Q3 2022 Portfolio in Review

As of Q3 2022, Opaleye Management held 53 positions worth $242M, up 9.1% from $222M the previous quarter. Its ten largest holdings account for 68% of the portfolio.

Opaleye Management withdrew a net $14.2M in Q3 2022, closing 11 positions and reducing 10 holdings. Its most notable exit was Kiniksa Pharmaceuticals, an estimated $7.89M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.

Against the trend, Opaleye Management opened a new position in Astria Therapeutics worth $1.21M.

  • Opaleye Management's largest Q3 2022 buy was Astria Therapeutics: 133,500 shares worth $1.21M.
  • Opaleye Management added most to Rhythm Pharmaceuticals in Q3 2022, an estimated $8.33M increase.
  • Opaleye Management's biggest Q3 2022 reduction was Inhibrx, Inc. Common Stock, cutting an estimated $5.36M.
  • Opaleye Management fully exited Kiniksa Pharmaceuticals in Q3 2022, selling an estimated $7.89M.
  • Opaleye Management's ten largest holdings make up 68% of its $242M portfolio in Q3 2022.
  • Opaleye Management opened 6 new positions and closed 11 in Q3 2022.
  • Opaleye Management's portfolio value rose 9.1% quarter-over-quarter to $242M.

Based on Opaleye Management's 13F filing for Q3 2022, filed 14 Nov 2022.